AMLN Financial Facts
Cost of goods sold: 34.56MResearch and development: 51.24M
See Full Income Statement
Deferred revenue, current portion: 7.5M
Restricted cash: 10.67M
See Full Balance Sheet
Amylin Pharmaceuticals, Inc. (AMLN) Earnings
|
Expand Research on AMLN
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -945.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +0.5% | Normal Earnings Time | N/A |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/26/12  |
 |
Q112 | -$0.23 | -$0.29 | +$0.06 | $153.7M | $161.66M | N/A |  | | Details |
| 2/6/12 |
|
Q411 | -$3.15 | -$0.08 | -$3.07 | $164.9M | $163.64M | N/A | | | Details |
| 10/19/11 |
|
Q311 | -$0.07 | -$0.15 | +$0.08 | $155.1M | $166.39M | N/A | | | Details |
| 7/26/11 |
|
Q211 | -$0.21 | -$0.18 | -$0.03 | $158.07M | $157.72M | N/A | | | Details |
| 4/18/11 |
|
Q111 | -$0.24 | -$0.23 | -$0.01 | $152.7M | $156.73M | N/A | | | Details |
| 11/4/10 |
|
Q310 | -$0.35 | -$0.35 | $0.00 | N/A | N/A | N/A | | | Details |
